Focal 18 F-FDG uptake predicts progression of pre-invasive squamous bronchial lesions to invasive cancers.

Autor: Smesseim I; Department of Pulmonary Diseases, Amsterdam University Medical Center, Location Free University Medical Center, Amsterdam, The Netherlands., van Boerdonk RA; Department of Pathology, Amsterdam University Medical Center, Amsterdam, The Netherlands., Dickhoff C; Department of Cardiothoracic Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands., Heineman DJ; Department of Cardiothoracic Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands., Dahele MR; Department of Radiotherapy, Amsterdam University Medical Center, Amsterdam, The Netherlands., Radonic T; Department of Pathology, Amsterdam University Medical Center, Amsterdam, The Netherlands., Bahce I; Department of Pulmonary Diseases, Amsterdam University Medical Center, Location Free University Medical Center, Amsterdam, The Netherlands., Rauh SP; Department of Epidemiology and Biostatistics, Amsterdam University Medical Center, Amsterdam, The Netherlands., Comans EFI; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands., Daniels HJMA; Department of Pulmonary Diseases, Amsterdam University Medical Center, Location Free University Medical Center, Amsterdam, The Netherlands.
Jazyk: angličtina
Zdroj: Thoracic cancer [Thorac Cancer] 2023 Mar; Vol. 14 (9), pp. 840-847. Date of Electronic Publication: 2023 Feb 18.
DOI: 10.1111/1759-7714.14815
Abstrakt: Introduction: Pre-invasive squamous lesions of the central airways can progress into invasive lung cancers. Identifying these high-risk patients could enable detection of invasive lung cancers at an early stage. In this study, we investigated the value of 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) scans in predicting progression in patients with pre-invasive squamous endobronchial lesions.
Methods: In this retrospective study, patients with pre-invasive endobronchial lesions, who underwent an 18 F-FDG PET scan at the VU University Medical Center Amsterdam, between January 2000 and December 2016, were included. Autofluorescence bronchoscopy (AFB) was used for tissue sampling and was repeated every 3 months. The minimum and median follow-up was 3 and 46.5 months. Study endpoints were the occurrence of biopsy proven invasive carcinoma, time-to-progression and overall survival (OS).
Results: A total number of 40 of 225 patients met the inclusion criteria of which 17 (42.5%) patients had a positive baseline 18 F-FDG PET scan. A total of 13 of 17 (76.5%) developed invasive lung carcinoma during follow-up, with a median time to progression of 5.0 months (range, 3.0-25.0). In 23 (57.5%) patients with a negative 18 F-FDG PET scan at baseline, 6 (26%) developed lung cancer, with a median time to progression of 34.0 months (range, 14.0-42.0 months, p < 0.002). With a median OS of 56.0 months (range, 9.0-60.0 months) versus 49.0 months (range, 6.0-60.0 months) (p = 0.876) for the  18 F-FDG PET positive and negative groups, respectively.
Conclusions: Patients with pre-invasive endobronchial squamous lesions and a positive baseline 18 F-FDG PET scan were at high-risk for developing lung carcinoma, highlighting that this patient group requires early radical treatment.
(© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje